Merck KGaA (FRA:MRK) Given a €82.00 Price Target by Barclays Analysts

Barclays set a €82.00 ($95.35) price target on Merck KGaA (FRA:MRK) in a report released on Monday, Borsen Zeitung reports. The brokerage currently has a sell rating on the healthcare company’s stock.

MRK has been the topic of a number of other reports. JPMorgan Chase & Co. set a €100.00 ($116.28) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, September 12th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the stock a buy rating in a research note on Monday, June 17th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, July 30th. Sanford C. Bernstein set a €114.00 ($132.56) price target on Merck KGaA and gave the stock a neutral rating in a research note on Wednesday, October 9th. Finally, Independent Research set a €103.00 ($119.77) price target on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the company’s stock. Merck KGaA has a consensus rating of Hold and a consensus price target of €101.33 ($117.83).

MRK stock opened at €106.30 ($123.60) on Monday. The stock’s 50 day simple moving average is €100.67 and its 200 day simple moving average is €95.75. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit